BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33824480)

  • 21. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
    Mariuzza RA; Shahid S; Karade SS
    J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
    Cao L; Dai C; Qin R; Guo Y; Liu J
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
    [No Abstract]   [Full Text] [Related]  

  • 23. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
    Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
    Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
    Liu X; Bao X; Hu M; Chang H; Jiao M; Cheng J; Xie L; Huang Q; Li F; Li CY
    Nature; 2020 Dec; 588(7839):693-698. PubMed ID: 33177715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity.
    Donlon NE; Power R; Hayes C; Reynolds JV; Lysaght J
    Cancer Lett; 2021 Apr; 502():84-96. PubMed ID: 33450360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    He Y; Sun L; Xu Y; Fu L; Li Y; Bao X; Fu H; Xie C; Lou L
    Cancer Lett; 2018 Apr; 420():49-59. PubMed ID: 29409989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human
    Burova E; Hermann A; Dai J; Ullman E; Halasz G; Potocky T; Hong S; Liu M; Allbritton O; Woodruff A; Pei J; Rafique A; Poueymirou W; Martin J; MacDonald D; Olson WC; Murphy A; Ioffe E; Thurston G; Mohrs M
    Mol Cancer Ther; 2019 Nov; 18(11):2051-2062. PubMed ID: 31395688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Plasticity and Resistance to Immunotherapy.
    Horn LA; Fousek K; Palena C
    Trends Cancer; 2020 May; 6(5):432-441. PubMed ID: 32348738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.
    Liu Y; Zheng P
    Trends Pharmacol Sci; 2020 Jan; 41(1):4-12. PubMed ID: 31836191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
    Li Y; Zhang Y; Cao G; Zheng X; Sun C; Wei H; Tian Z; Xiao W; Sun R; Sun H
    J Hematol Oncol; 2021 Jun; 14(1):100. PubMed ID: 34174928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
    Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
    Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
    Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples.
    Liu Q; Qi Y; Zhai J; Kong X; Wang X; Wang Z; Fang Y; Wang J
    Front Immunol; 2021; 12():599207. PubMed ID: 34267742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LAG3's Enigmatic Mechanism of Action.
    Graydon CG; Mohideen S; Fowke KR
    Front Immunol; 2020; 11():615317. PubMed ID: 33488626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
    Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
    Lecocq Q; Keyaerts M; Devoogdt N; Breckpot K
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.